Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12723MR)

This product GTTS-WQ12723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12723MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9914MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ4823MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ1526MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ9023MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ1638MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ5938MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ3597MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ10897MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW